Business Wire: Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA ® (voxelotor) From Worldwide Markets
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA ® (voxelotor) From Worldwide Markets
CNBC: Every Cure’s drug repurposing strategy isn't what you think, and it could change rare disease treatment
Every Cure’s drug repurposing strategy isn't what you think, and it could change rare disease treatment
Liver disease surge among young Indians and smaller cities drives rising claims and costs, pushing insurers to rethink coverage, prevention and policy sizes ...
Parkinson’s disease often begins asymmetrically, affecting either the right or left side of the body first. Researchers from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) ...
Parkinson’s disease is more common than previous research has shown, affecting 50 percent more people annually than past estimaes, according to a new study published Thursday in the academic journal ...
In advanced cancers, including breast, lung, and melanoma, leptomeningeal disease (LMD), a condition associated with rapid neurological deterioration, can develop. Treatment options remain limited, ...
Yes. Treatments for substance use disorders can help a person stop or reduce their drug use, help prevent a return to use (relapse), alleviate the negative consequences associated with their drug use, and help them regain the ability to function successfully at work, in their family, and in their community.